Video

Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

Author(s):

Neal Shore, MD, FACS

Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.

Current Time 0:00
Duration 2:51
Loaded: 5.73%
Stream Type LIVE
Remaining Time 2:51
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
    Data link incontinence severity to post-radical prostatectomy care
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
    Expert discusses differentiating prostate cancer from age-related issues
    Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
    Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
    Ruben Olivares, MD, answers a question during a Zoom video interview
    Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
    Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
    Strategies to bridge gender disparities in AAS and citations in the oncology literature
    Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
    Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
    1 expert in this video
    Selecting Between Receptor Pathway Inhibitors for mHSPC
    1 expert in this video
    The Use of Ultra-Low PSA in Specific Patient Profiles
    Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
    Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
    Related Content
    FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
    June 20th 2025

    FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

    Hannah Clarke
    The phase 1 study is set to begin later this year.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Real-world studies compare overall survival between ARPIs in mCSPC
    June 19th 2025

    Real-world studies compare overall survival between ARPIs in mCSPC

    Mehmet Asim Bilen, MD Hannah Clarke
    "Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
    June 17th 2025

    Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

    Hannah Clarke
    ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
    FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
    June 17th 2025

    FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

    Hannah Clarke
    Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
    © 2025 MJH Life Sciences

    All rights reserved.